Phosphopantetheinyl transferases (PPTases) are essential enzymes that catalyze covalent attachment of the 4'-phosphopantetheine (4'-PP) moiety from coenzyme A (CoA) to a conserved serine residue on acyl (ACP) and peptidyl carrier proteins (PCP) [1]. This posttranslational modification converts the inactive apo-carrier proteins to the functional form, shuttling the intermediates of biosynthetic reactions catalyzed by fatty acid synthases (FAS), polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPSs). In Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), two PPTases, AcpS (type-I) and PptT (type-II), are involved in the biosynthesis of essential lipids, virulence factors and siderophores, activating over 20 target proteins [2]. These two proteins have been shown to be independently essential, suggesting that PPTases could be targeted against tuberculosis [2, 3]. We have expressed the Mtb-PptT protein as a fusion protein with maltose binding protein (MBP). The use of the MBP-PptT fusion protein overcame stability and solubility problems and resulted in successful crystallization. The structure of Mtb-PptT in complex with CoA was determined from the crystal of the fusion protein, solved at 1.75 Å resolution. Excellent electron density is present for all parts of the CoA molecule, revealing a conserved CoA-binding mode. Conformational and charge distribution differences in the putative ACP binding cleft, however, suggest a different mode of ACP binding compared to other homologues. This is the first and only threedimensional structure of a type-II PPTase from pathogenic bacteria, providing structural features that can be exploited in drug development when compared with its human counterpart. 
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